RYVU Therapeutics S.A.

Management Reports • Dec 31, 2025

Report Content Receipt of a notification pursuant to Article 69 of the Act on PublicOffering

The Management Board of Ryvu Therapeutics S.A., with its registeredoffice in Kraków (the "Company"), hereby informs that on December 31,2025 it received notifications from the Company's shareholder, Mr.Bogusław Sieczkowski, and CapitalS Family Foundation in organization -an entity closely related to Mr. Bogusław Sieczkowski, prepared pursuantto Article 69(1)(1) and Article 69a(1)(3) of the Act of July 29, 2005 onPublic Offering, the Conditions Governing the Introduction of FinancialInstruments to an Organized Trading System and Public Companies.

As a result of the event described in the above-mentioned notifications,all shares of the Company previously held by Mr. Bogusław Sieczkowski,i.e. 825,348 shares representing 3.57% of the Company's share capitaland 5.06% of the total number of votes at the General Meeting of theCompany, were transferred by way of a donation agreement to an entityclosely related to him, namely CapitalS Family Foundation inorganization.

As a consequence, the share of CapitalS Family Foundation inorganization in the total number of votes at the General Meeting of theCompany exceeded the 5% threshold and amounts to 5.06% of the totalnumber of votes at the General Meeting of the Company.

The share of Mr. Bogusław Sieczkowski in the total number of votes atthe General Meeting of the Company, held indirectly through an entityclosely related to him, i.e. CapitalS Family Foundation in organization,has not changed and amounts to 5.06%.

The full text of the notifications is attached to this current report.

Disclaimer: This English language translation has been prepared solelyfor the convenience of English-speaking readers. Despite all the effortsdevoted to this translation, certain discrepancies, omissions orapproximations may exist. In case of any differences between the Polishand the English versions, the Polish version shall prevail. RyvuTherapeutics S.A., its representatives and employees decline allresponsibility in this regard.